Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912

Tait D. Shanafelt, Stanford University School of Medicine, Stanford, California, United States.
Xin Victoria Wang, Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts, United States.
Curtis A. Hanson, Mayo Clinic, Rochester, Minnesota, United States.
Elisabeth Paietta, Montefiore Medical Center, Bronx, New York, United States.
Susan M. O'Brien, Chao Family Comprehensive Cancer Center at UC Irvine Medical Center, Orange, California, United States.
Jacqueline Claudia Barrientos, Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach, Florida, United States.
Diane F. Jelinek, Mayo Clinic, Scottsdale, Arizona, United States.
Esteban Braggio, Mayo Clinic Arizona, Scottsdale, Arizona, United States.
Jose F. Leis, Mayo Clinic, Phoenix, Arizona, United States.
Cong Zhang, Kaiser Permanente NCORP, Fresno, California, United States.
Paul M. Barr, Wilmot Cancer Institute, University of Rochester, Rochester, New York, United States.
Amanda F. Cashen, Washington University School of Medicine, St Louis, Missouri, United States.
Anthony R. Mato, Memorial Sloan Kettering Cancer Center, United States.
Avina K. Singh, Minnesota Oncology, Burnsville, Minnesota, United States.
Michael Mullane, Advocate Health - MidwestFollow
Richard F. Little, National Cancer Institute, Bethesda, Maryland, United States.
Harry P. Erba, Duke University, Durham, North Carolina, United States.
Richard M. Stone, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
Mark R. Litzow, Mayo Clinic, Rochester, Minnesota, United States.
Martin S. Tallman, Memorial Sloan Kettering Cancer Center, United States.
Neil E. Kay, Mayo Clinic, Rochester, Minnesota, United States.

Affiliations

Aurora Health Care, Mount Pleasant

Type

Article

PubMed ID

39163612

Link to Full Text

 

Share

COinS